Form 4: Astrana Health Director David Schmidt Receives Restricted Stock Grant

Astrana Health, Inc. Director David Schmidt was granted 6,449 shares of restricted common stock on June 11, 2025, as part of the company's 2024 Equity Incentive Plan.

Summary

• David Schmidt, a Director of Astrana Health, Inc. (ASTH), acquired 6,449 shares of common stock on June 11, 2025.
• The acquisition was a grant of restricted shares under the Issuer's 2024 Equity Incentive Plan, with a transaction price of $0 per share.
• These restricted shares are set to vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Following this transaction, David Schmidt beneficially owns a total of 15,763 shares of common stock, which includes the newly granted 6,449 restricted shares.

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of restricted stock aligns the director's interests with shareholders, which is generally viewed favorably. It's a standard compensation practice and not indicative of negative company performance or issues.

Positives

• The grant of restricted stock to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction designed to comply with insider trading regulations.

Future Outlook

The 6,449 restricted shares granted to Director David Schmidt are scheduled to vest on the earlier of June 11, 2026, or the date of Astrana Health's 2026 annual meeting of stockholders, indicating a future milestone for this equity compensation.

Industry Context

The grant of restricted stock to directors is a common and standard practice across various industries, particularly in publicly traded companies, as a form of long-term incentive compensation designed to align the interests of directors with those of the company's shareholders.

Comparison to Industry Standards

• The grant of restricted stock to a director is a standard component of executive and director compensation packages in publicly traded companies, comparable to practices at peers in the healthcare services sector.
• The use of an Equity Incentive Plan (specifically the 2024 plan) for such grants is a typical corporate governance mechanism for distributing equity-based compensation, similar to plans adopted by companies like UnitedHealth Group (UNH) or CVS Health (CVS) for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of restricted stock to David Schmidt, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially leading to more shareholder-centric decision-making.

Next Steps

• Vesting of the 6,449 restricted shares on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Astrana Health, ASTH, David Schmidt, Restricted Stock, Equity Incentive Plan, Director Compensation, Insider Transaction, Form 4, SEC Filing